PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3β pathway

Journal of Molecular and Cellular Cardiology

Volumn 41, Issue 1, 2006, Pages 149-159

  Palfi, Anita ^a,b   Toth, Ambrus ^b   Hanto, Katalin ^a,b   Deres, Peter ^a,b   Szabados, Eszter ^a   Szereday, Zoltan ^b   Kulcsar, Gyozo ^b   Kalai, Tamas ^b   Hideg, Kalman ^b   Gallyas Jr , Ferenc ^b   Sumegi, Balazs ^b,c   Toth, Kalman ^a   Halmosi, Robert ^a  

^a School of Medicine   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Glycogen synthase kinase 3 ; Heart failure; Intracellular signaling; PARP inhibition; Protein kinase C; Ventricular remodeling

Indexed keywords

2 [(2 PIPERIDIN 1 YLETHYL)THIO]QUINAZOLIN 4(3H) ONE; 2 [2 (1 PIPERIDINYL)ETHYLTHIO] 4(3H) QUINAZOLINONE; COLLAGEN; GLYCOGEN SYNTHASE KINASE 3BETA; ISOPRENALINE; MITOCHONDRIAL ENZYME; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C BETAII; PROTEIN KINASE C EPSILON; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EMBRYO; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EXPERIMENTAL MODEL; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANIMALS; CARDIOMEGALY; COLLAGEN TYPE III; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HEART FAILURE, CONGESTIVE; ISOPROTERENOL; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PHOSPHORYLATION; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE C; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 33745391346     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.03.427     Document Type: Article

References (44)

1. Virag L., and Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54 (2002) 375-429
2. Szabo G., Liaudet L., Hagl S., and Szabo C. Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovasc Res 61 (2004) 471-480
3. Lopez Farre A., and Casado S. Heart failure, redox alterations, and endothelial dysfunction. Hypertension 38 (2001) 1400-1405
4. Dhalla A.K., and Singal P.K. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am J Physiol 266 (1994) H1280-H1285
5. Lips D.J., de Windt L.J., van Kraaij D.J., and Doevendans P.A. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 24 (2003) 883-896
6. Yamazaki T., and Yazaki Y. Molecular basis of cardiac hypertrophy. Z Kardiol 89 (2000) 1-6
7. Haq S., Choukroun G., Lim H., Tymitz K.M., del Monte F., Gwathmey J.L., et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 103 (2001) 670-677
8. Palfi A., Toth A., Kulcsar G., Hanto K., Deres P., Bartha E., et al. The role of Akt and MAP kinase systems in the protective effect of PARP inhibition in Langendorff perfused and in isoproterenol damaged rat hearts. J Pharmacol Exp Ther 315 (2005) 273-282
9. Habon T., Szabados E., Kesmarky G., Halmosi R., Past T., Sumegi B., et al. The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals. Cardiovasc Res 52 (2001) 153-160
10. Fowler M.B. Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure. Am J Cardiol 93 (2004) 35B-39B
11. Zingarelli B., Hake P.W., O'Connor M., Denenberg A., Wong H.R., Kong S., et al. Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1. Am J Physiol, Heart Circ Physiol 286 (2004) H1408-H1415
12. Zingarelli B., Hake P.W., O'Connor M., Denenberg A., Kong S., and Aronow B.J. Absence of poly(ADP-ribose) polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury. Mol Med 9 (2003) 143-153
13. Antos C.L., McKinsey T.A., Frey N., Kutschke W., McAnally J., Shelton J.M., et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99 (2002) 907-912
14. van Bilsen M., Smeets P.J., Gilde A.J., and van der Vusse G.J. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome?. Cardiovasc Res 61 (2004) 218-226
15. Tan F.L., Moravec C.S., Li J., Apperson-Hansen C., McCarthy P.M., Young J.B., et al. The gene expression fingerprint of human heart failure. Proc Natl Acad Sci USA 99 (2002) 11387-11392
16. Sun Y., Zhang J.Q., Zhang J., and Lamparter S. Cardiac remodeling by fibrous tissue after infarction in rats. J Lab Clin Med 135 (2000) 316-323
17. Veres B., Radnai B., Gallyas Jr. F., Varbiro G., Berente Z., Osz E., et al. Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in LLP-induced inflammation in mice. J Pharmacol Exp Ther 310 (2004) 247-255
18. Tapodi A., Debreceni B., Hanto K., Bognar Z., Wittmann I., Gallyas Jr. F., et al. Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose) polymerase-1 inhibition in oxidative stress. J Biol Chem 280 (2005) 35767-35775
19. Teerlink J.R., Pfeffer J.M., and Pfeffer M.A. Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 75 (1994) 105-113
20. Kulcsar G., Kalai T., Osz E., Sar P.C., Jeko J., Sumegi B., et al. Synthesis and study of new 4-quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). ARKIVOC (2003) 121-131
21. Pacher P., Liaudet L., Mabley J., Komjati K., and Szabo C. Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol 40 (2002) 1006-1016
22. Halmosi R., Berente Z., Osz E., Toth K., Literati-Nagy P., and Sumegi B. Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system. Mol Pharmacol 59 (2001) 1497-1505
23. Wang Y., Huang S., Sah V.P., Ross Jr. J., Brown J.H., Han J., et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273 (1998) 2161-2168
24. Grimm D., Elsner D., Schunkert H., Pfeifer M., Griese D., Bruckschlegel G., et al. Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. Cardiovasc Res 37 (1998) 91-100
25. Cleland J.G., Swedberg K., Follath F., Komajda M., Cohen-Solal A., Aguilar J.C., et al., Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme-A survey on the quality of care among patients with heart failure in Europe: Part 1. Patient characteristics and diagnosis. Eur Heart J 24 (2003) 442-463
26. Ogawa Y., Itoh H., and Nakao K. Molecular biology and biochemistry of natriuretic peptide family. Clin Exp Pharmacol Physiol 22 (1995) 49-53
27. Hystad M.E., Klinge R., Spurkland A., Attramadal H., and Hall C. Contrasting cardiac regional responses of A-type and B-type natriuretic peptide to experimental chronic heart failure. Scand J Clin Lab Invest 60 (2000) 299-309
28. Clerico A., and Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 50 (2004) 33-50
29. Kim S., and Iwao H. Activation of mitogen-activated protein kinases in cardiovascular hypertrophy and remodeling. Jpn J Pharmacol 80 (1999) 97-102
30. Hardt S.E., Tomita H., Katus H.A., and Sadoshima J. Phosphorylation of eukaryotic translation initiation factor 2Bepsilon by glycogen synthase kinase-3beta regulates beta-adrenergic cardiac myocyte hypertrophy. Circ Res 94 (2004) 926-935
31. Haq S., Choukroun G., Kang Z.B., Ranu H., Matsui T., Rosenzweig A., et al. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 151 (2000) 117-130
32. Liao P., Georgakopoulos D., Kovacs A., Zheng M., Lerner D., Pu H., et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci USA 98 (2001) 12283-12288
33. Molkentin J.D. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res 87 (2000) 731-738
34. Condorelli G., Drusco A., Stassi G., Bellacosa A., Roncarati R., Iaccarino G., et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 99 (2002) 12333-12338
35. Ballou L.M., Tian P.Y., Lin H.Y., Jiang Y.P., and Lin R.Z. Dual regulation of glycogen synthase kinase-3beta by the alpha1A-adrenergic receptor. J Biol Chem 276 (2001) 40910-40916
36. Fang X., Yu S., Tanyi J.L., Lu Y., Woodgett J.R., and Mills G.B. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22 (2002) 2099-2110
37. Braun M.U., Szalai P., Strasser R.H., and Borst M.M. Right ventricular hypertrophy and apoptosis after pulmonary artery banding: regulation of PKC isozymes. Cardiovasc Res 59 (2003) 658-667
38. Koide Y., Tamura K., Suzuki A., Kitamura K., Yokoyama K., Hashimoto T., et al. Differential induction of protein kinase C isoforms at the cardiac hypertrophy stage and congestive heart failure stage in Dahl salt-sensitive rats. Hypertens Res 26 (2003) 421-426
39. Braun M., Simonis G., Birkner K., Pauke B., and Strasser R.H. Regulation of protein kinase C isozyme and calcineurin expression in isoproterenol induced cardiac hypertrophy. J Cardiovasc Pharmacol 41 (2003) 946-954
40. Bayer A.L., Heidkamp M.C., Patel N., Porter M., Engman S., and Samarel A.M. Alterations in protein kinase C isoenzyme expression and autophosphorylation during the progression of pressure overload-induced left ventricular hypertrophy. Mol Cell Biochem 242 (2003) 145-152
41. Gopalakrishna R., and Jaken S. Protein kinase C signaling and oxidative stress. Free Radic Biol Med 28 (2000) 1349-1361
42. Du X., Matsumura T., Edelstein D., Rossetti L., Zsengeller Z., Szabo C., et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112 (2003) 1049-1057
43. Minchenko A.G., Stevens M.J., White L., Abatan O.I., Komjati K., Pacher P., et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 17 (2003) 1514-1516
44. Janero D.R., Hreniuk D., and Sharif H.M. Hydroperoxide-induced oxidative stress impairs heart muscle cell carbohydrate metabolism. Am J Physiol 266 (1994) C179-C188